ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L02BA03 | G | Fulvestrant - 250mg/5ml | 10988 | 79521/1 | FULVESTRANT EVER PHARMA | 250mg | 2x5ml | Injectable solution | IM | Codipha | Ever Pharma Jena GmbH | Germany | 31,059,148 L.L | 19.35 | D | Ever Valinject GmbH | Austria | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L02BA03 | B | Fulvestrant - 250mg/5ml | 6863 | 97210/12 | FASLODEX | 250mg/5ml | 2 | Injectable solution | IM | Omnipharma | Vetter Pharma- Fertigung GmbH & Co KG | Germany | 46,628,557 L.L | 10.71 | E1 | AstraZeneca UK Ltd | UK | 2/5/2024 | 0 |
L02BA03 | G | Fulvestrant - 250mg/5ml | 10449 | 56020/1 | FUXRAN | 250mg/5ml | 2 | Injectable solution | IM | Khalil Fattal & Fils S.A.L. | Fareva Unterach GmbH | Austria | 36,771,714 L.L | 10.71 | E1 | Sandoz Pharmaceuticals AG | Switzerland | 2/5/2024 | 0 |
L02BA03 | B | Fulvestrant - 250mg/5ml | 6863/388 | 97210/12 | FASLODEX | 250mg/5ml | 2 | Injectable solution | IM | Omnipharma | Vetter Pharma- Fertigung GmbH & Co KG | Germany | L.L | 10.71 | E1 | AstraZeneca UK Ltd | UK | 2/5/2024 |